Abstract
Antivascular approaches aim to cause rapid and catastrophic shutdown in the vascular function of the tumour, leading to extensive tumour cell death. Tumour vascular disrupting agents (VDAs) are a new class of cancer therapies that target the existing vasculature of tumours, taking advantage of the relative instability of tumour vasculature and its supporting structures. Treatment with VDAs induces a rapid collapse and regression of tumour vessels, with a consequent deprivation of blood and oxygen which leads to ischemic or hemorrhagic necrosis of the tumour. In this review, an overview of the most recently developed vascular disrupting agents is reported, focusing on the biological effects exerted by these compounds on endothelial cells and tumour vasculature, potentially effective in the treatment of several malignancies including upper gastrointestinal tumours. In particular, we have focused on the antimitotic agent combretastatin and its numerous synthetic analogues such as combretastatin A-4-phosphate, OXI4503, and AVE8062, and on the colchicine analogue ZD6126.
Keywords: Gastrointestinal cancers, upper gastrointestinal malignancies, vascular disrupting agents.
Current Medicinal Chemistry
Title:New Vascular Disrupting Agents in Upper Gastrointestinal Malignancies
Volume: 21 Issue: 8
Author(s): A.E. Quatrale, L. Porcelli, A. Gnoni, G. Numico, A. Paradiso and A. Azzariti
Affiliation:
Keywords: Gastrointestinal cancers, upper gastrointestinal malignancies, vascular disrupting agents.
Abstract: Antivascular approaches aim to cause rapid and catastrophic shutdown in the vascular function of the tumour, leading to extensive tumour cell death. Tumour vascular disrupting agents (VDAs) are a new class of cancer therapies that target the existing vasculature of tumours, taking advantage of the relative instability of tumour vasculature and its supporting structures. Treatment with VDAs induces a rapid collapse and regression of tumour vessels, with a consequent deprivation of blood and oxygen which leads to ischemic or hemorrhagic necrosis of the tumour. In this review, an overview of the most recently developed vascular disrupting agents is reported, focusing on the biological effects exerted by these compounds on endothelial cells and tumour vasculature, potentially effective in the treatment of several malignancies including upper gastrointestinal tumours. In particular, we have focused on the antimitotic agent combretastatin and its numerous synthetic analogues such as combretastatin A-4-phosphate, OXI4503, and AVE8062, and on the colchicine analogue ZD6126.
Export Options
About this article
Cite this article as:
Quatrale A.E., Porcelli L., Gnoni A., Numico G., Paradiso A. and Azzariti A., New Vascular Disrupting Agents in Upper Gastrointestinal Malignancies, Current Medicinal Chemistry 2014; 21 (8) . https://dx.doi.org/10.2174/09298673113209990233
DOI https://dx.doi.org/10.2174/09298673113209990233 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Erlotinib and Gefitinib for Elderly Patients with Advanced Non-small-cell Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry Heat Shock Protein 90 Inhibitors as Broad Spectrum Anti-Infectives
Current Pharmaceutical Design Side Effects of AAS Abuse: An Overview
Mini-Reviews in Medicinal Chemistry The Water Channels, New Druggable Targets to Combat Cancer Cell Survival,Invasiveness and Metastasis
Current Drug Targets <I>Prunus Armeniaca L</I>. Seed Extract and Its Amygdalin Containing Fraction Induced Mitochondrial-Mediated Apoptosis and Autophagy in Liver Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry Bcl-2 Inhibitors: Emerging Drugs in Cancer Therapy
Current Medicinal Chemistry Redox Signaling Pathways Involved in Neuronal Ischemic Preconditioning
Current Neuropharmacology Prophylactic Admission of an In Vitro Reconstructed Complexes of Human Recombinant Heat Shock Proteins and Melanoma Antigenic Peptides Activates Anti-Melanoma Responses in Mice
Current Molecular Medicine Regulation of Angiogenesis by the Small Heat Shock Protein αB-Crystallin
Current Angiogenesis (Discontinued) Therapeutic Antibodies
Current Molecular Medicine Tubulins as Therapeutic Targets in Cancer: from Bench to Bedside
Current Pharmaceutical Design Chronic Exposure to Low-Level Cadmium in Diabetes: Role of Oxidative Stress and Comparison with Polychlorinated Biphenyls
Current Drug Targets Discovery, SAR and Medicinal Chemistry of Herpesvirus Helicase Primase Inhibitors
Current Medicinal Chemistry - Anti-Infective Agents Therapeutic Drug Monitoring of Targeted Therapy in Metastatic Renal Cell Carcinoma
Protein & Peptide Letters Inhibition of the Histone Lysine Methyltransferase EZH2 for the Treatment of Cancer
Current Topics in Medicinal Chemistry Endometrial Cancer as a Familial Tumor: Pathology and Molecular Carcinogenesis (Review)
Current Genomics ADAM19/Adamalysin 19 Structure, Function, and Role as a Putative Target in Tumors and Inflammatory Diseases
Current Pharmaceutical Design Current Status of Thalidomide and CC-5013 in the Treatment of Metastatic Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry First Ayurvedic Approach Towards Green Drugs: Anti Cervical Cancer-Cell Properties of Clerodendrum viscosum Root Extract
Anti-Cancer Agents in Medicinal Chemistry CYP3A4-mediated Pharmacokinetic Interactions in Cancer Therapy
Current Drug Metabolism